REGENXBIO (NASDAQ:RGNX) Stock Price Up 13.6% – Time to Buy?

REGENXBIO Inc. (NASDAQ:RGNX) shares traded up 13.6% during mid-day trading on Wednesday. The company traded as high as $8.68 and last traded at $8.7350. 729,159 shares were traded during trading, a decline of 49% from the average daily volume of 1,426,370 shares. The stock had previously closed at $7.69.

Key REGENXBIO News

Investors following RGNX have been watching these news items:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.15 from a loss of $3.65, while maintaining its Buy rating. REGENXBIO analyst coverage
• Neutral Sentiment: A short-interest update reports zero shares sold short and zero days to cover, despite describing a “significant increase.” The conflicting wording makes the data difficult to interpret and does not provide a clear directional signal.
• Negative Sentiment: HC Wainwright lowered EPS estimates for Q4 2026 and each quarter of 2027, and cut its FY2027 estimate to a loss of $4.41 from $4.02. The deeper projected losses may weigh on sentiment, although the firm retained its Buy rating. REGENXBIO analyst coverage

Wall Street Analyst Weigh In

RGNX has been the subject of several research reports. UBS Group reaffirmed a “positive” rating on shares of REGENXBIO in a research report on Friday, November 6th. Zacks Research upgraded shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a research note on Saturday. Morgan Stanley restated an “overweight” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Friday, August 7th. Finally, Robert W. Baird reduced their price objective on shares of REGENXBIO from $32.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.18.

REGENXBIO Stock Up 12.6%

The business has a 50-day simple moving average of $7.74 and a two-hundred day simple moving average of $8.98. The stock has a market capitalization of $571.47 million, a P/E ratio of -2.70 and a beta of 1.24.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.67. REGENXBIO had a negative return on equity of 203.98% and a negative net margin of 113.85%. The company had revenue of $9.16 million during the quarter, compared to analysts’ expectations of $10.89 million. On average, sell-side analysts forecast that REGENXBIO Inc. will post -3.10 earnings per share for the current year.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in REGENXBIO during the 2nd quarter valued at about $76,641,000. Bank of America Corp DE acquired a new position in REGENXBIO in the second quarter valued at about $6,212,000. Corient Private Wealth LP acquired a new position in REGENXBIO in the second quarter valued at about $2,608,000. Deutsche Bank AG bought a new stake in REGENXBIO during the second quarter worth about $2,490,000. Finally, Walleye Capital LLC bought a new stake in REGENXBIO during the second quarter worth about $2,441,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc. is a biotechnology company focused on developing gene therapies for inherited diseases and other serious conditions. Founded in 2008 and headquartered in Rockville, Maryland, the company uses its proprietary NAV AAV gene-delivery platform to develop treatments intended to deliver genetic material to patients’ cells. Its research programs have included RGX-314, an investigational gene therapy for retinal diseases such as wet age-related macular degeneration, and candidates for conditions including Hunter syndrome and Duchenne muscular dystrophy.